Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
Von willebrand factor, Quantity: 1200 IU; Factor VIII, Quantity: 500 IU
CSL Behring Australia Pty Ltd
Factor VIII,Von willebrand factor
Injection, diluent for
Excipient Ingredients: water for injections
Intravenous
500 IU FVIII/1200 IU VWF
(S1) This Schedule is intentionally blank
Aleviate is indicated for: ? the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von Willebrand disease when desmopressin (DDAVP) treatment is ineffective or contraindicated. ? the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
Visual Identification: Clear colourless solution free from visible particles.; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Listed (Export Only)
2014-12-16